abstract: Cerebral palsy (CP) is a non-progressive neurologic disorder characterized by motor pathway damage prior to functional development. Damage to the central nervous system impairs motor functioning, including control of motor movement, loss of coordination, and loss of purposeful posture in individuals with cerebral palsy. This creates abnormal walking gait, impaired balance, and loss of muscle control. Current research shows positive results in studying the use of rhythmic music and walking gait for individuals with neurologic disorders. However, most research focuses on neurologic disorders acquired later in life, such as post-stroke patients and individuals with Parkinson's disease and traumatic brain injuries. The current study addresses the impact of rhythmic music on walking gait for an individual with cerebral palsy. Research addresses whether the use of rhythmic music impacts: (a) endurance (laps, distance traversed, and steps taken) (b) cadence (steps per minute), (c) velocity (distance over time), (d) emotional responsiveness (positive or negative affect), and (e) motivation. The current study is a single subject, mixed method design under randomized treatment conditions. The subject is a 25-year-old female diagnosed with spastic diplegic cerebral palsy. The subject participated in a five-week study, three times a week for one hour each session. Assessment was conducted during the first session. The following 14 sessions included gait training either under treatment (the use of recorded rhythmic music accompanied by audible drum beat) or control (no music) randomly assigned prior to the beginning of the study. Data were collected through video recordings, subject and researcher journals, and emotional responsiveness surveys. Data were analyzed for treatment versus control conditions. Analysis of both quantitative and qualitative data indicated that rhythmic music does impact walking gait for individuals with cerebral palsy. When compared to control conditions, the treatment conditions showed an increase in endurance, cadence, and velocity, and improvement in affect and motivation. / Dissertation/Thesis / M.M. Music Therapy 2011

No description available.

No description available.

No description available.

Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA), is a membrane metallopeptidase overexpressed on most prostate cancer cells. Additionally, GCPII also attracted neurologists' attention because it cleaves neurotransmitter N-acetyl-L-aspartyl-L-glutamate (NAAG). Since NAAG exhibits neuroprotective effects, GCPII may participate in a number of brain disorders, which were shown to be ameliorated by GCPII selective inhibitors. Therefore, GCPII has become a promising target for imaging and prostate cancer targeted therapy as well as therapy of neuronal disorders. Globally, prostate cancer represents the second most prevalent cancer in men. With the age, most men will develop prostate cancer. However, prostate tumors are life threatening only if they escape from the prostate itself and start to spread to other tissues. Therefore, considerable efforts have been made to discover tumors earlier at more curable stages as well as to target aggressive metastatic cancers that have already invaded other tissues and become resistant to the standard treatment. Since patients undergoing a conventional therapy (a combination of chemotherapy and surgery) suffer from severe side effects, more effective ways of treatment are being searched for. Novel approaches include selective...